作者
Joe Y Chang, Suresh Senan, Marinus A Paul, Reza J Mehran, Alexander V Louie, Peter Balter, Harry JM Groen, Stephen E McRae, Joachim Widder, Lei Feng, Ben EEM van den Borne, Mark F Munsell, Coen Hurkmans, Donald A Berry, Erik van Werkhoven, John J Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelis JA Haasbeek, Larry S Carpenter, Katrien De Jaeger, Ritsuko Komaki, Ben J Slotman, Egbert F Smit, Jack A Roth
发表日期
2015/6/1
期刊
The lancet oncology
卷号
16
期号
6
页码范围
630-637
出版商
Elsevier
简介
Background
The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials.
Methods
Eligible patients in the STARS and ROSEL studies were those with clinical T1–2a (<4 cm), N0M0, operable NSCLC. Patients were randomly assigned in a 1:1 ratio to SABR or lobectomy with mediastinal lymph node dissection or sampling. We did a pooled analysis in the intention-to-treat population using overall survival as the primary endpoint. Both trials are registered with ClinicalTrials.gov (STARS …
学术搜索中的文章
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie… - The lancet oncology, 2015